ClinicalTrials.gg
CompletedNCT04225884VIRPIUpdated Nov 8, 2023

Digital Therapeutics (DTx) for Pain: Pilot Study of a Virtual Reality Software for Chronic Pain

An interventional study of DTx for pain software and Control software in Chronic Low Back Pain, sponsored by Orion Corporation, Orion Pharma. Completed at 1 site in Finland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-08.

Sponsored by Orion Corporation, Orion Pharma · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Low Back Pain with a site in Finland — 3 open to participants now, 4 under way, none of them phase 3. Low Back Pain · Finland.

Enrollment
13th of 15
34 · median 175
Started
2020
the only one that year
No phase
13 of 16
3 open now
Registered
11th of 16
by date
Lead sponsor
1 of 16
Orion Corporation, Orion Pharma

Among the 16 studies in Low Back Pain with a site in Finland, this one is the 13th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2020, is one of 13 with no phase, and was the 11th registered.

Low Back Pain

2,930 studies on the registry are indexed under Low Back Pain; 581 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

3 of the 16 studies in Low Back Pain with a site in Finland are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Finland have not opened yet or have stopped. Only those recruiting at a site in Finland →

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Low Back Pain with a site in Finland, or all of them as a file.
02

Study summary

Prospective, randomised, double-blind, 3-arm parallel group comparison of 2 different virtual reality softwares and standard care.

Read the detailed description

Prospective, randomised, double-blind, 3-arm parallel group comparison of DTx for pain (treatment A), control (treatment B) and an open standard care arm, over 6-8 weeks. An optional adaptive, multi-objective, multi-purpose, extension is included. Study devices will be delivered to the patient's home with instructions for use; patients will receive remote technical support.

03

Conditions studied

  • Chronic Low Back Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Competent male or female adults (age ≥ 18 years).
  • Chronic low back pain
  • Written
  • Finnish speaking
  • having a clear, flat surface of at least 2 x 2 m of size to interact with DTx for pain
  • Can stoop without severe pain

Exclusion criteria

Exclusion Criteria:

  • History of epilepsy, migraine, vertigo or psychosis
  • Confirmed diagnosis of cancer
  • Prone to strong motion sickness requiring treatment
  • Pregnancy
  • Physiotherapy based interventions
  • Severe or acute structural pathologies (e.g. spondylitis, epidural abscess, spondylolisthesis, acute herniated or ruptured disc, traumatic injury, or severe spinal stenosis) that could be worsened by the intervention as assessed by the principal investigator
  • Has received (in last 2 years) or is receiving formal psychotherapy from a psychologist for pain or allied health care professional at the screening stage
  • Any other condition that would affect posture or balance, and
  • Prior participation in DTx for pain feasibility study or in any part of the current study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
34 participants (actual)

Study arms

  • Active comparator
    DTx for pain

    Treatment A software

    Other: DTx for pain software

  • Sham comparator
    Control

    Treatment B software

    Other: Control software

  • Other
    Standard care

    Pain medication

    Other: Standard care

Interventions

  • OtherDTx for pain software

    Software with active intervention

  • OtherControl software

    Software without active intervention

  • OtherStandard care

    Pain medication

06

What researchers measure

Primary outcomes

  1. Self-report of disability, Oswestry

    Oswestry Disability Index (subjects with a score of ≤22 will be considered as responders), index 0%-100% (0=no disability, 100=maximum disability possible).

    Time frame: From randomisation upto 6-8 weeks

  2. Self-report of disability; Pain Interference

    The Patient Reported Outcomes Information System (PROMIS) 6b - Pain Interference Scale, score 6-30 (6=pain not at all interfering patient's life, 30=maximum interfering to patient's life).

    Time frame: From randomisation upto 6-8 weeks

  3. Objective report of disability, steps

    Average number of steps per day over one week, as assessed by wearable equipment, 0-maximum amount of steps (0=patient not taking steps at all, maximum disability; maximum number of steps=minimum disability).

    Time frame: From randomisation upto 6-8 weeks

  4. Fear of movement and re-injury

    Tampa Scale of Kinesiophobia (TSK), score 17-68 (17=negligible or no kinesiophobia,68=extreme fear of pain with movement).

    Time frame: From randomisation upto 6-8 weeks

  5. Pain Behaviour, pain intensity

    Numerical Rating Scale, PROMIS 3a - Pain Intensity Scale, score 3-15 (3=no pain,15=very severe pain).

    Time frame: From randomisation upto 6-8 weeks

  6. Pain Behaviour, pain medications

    Any changes in pain medication during the study period are reported as outcome.

    Time frame: From randomisation upto 6-8 weeks

  7. Quality of life, own experience

    EuroQol-5D-5L-scale: European Quality (EQ) of Life (l), 5-dimension-5-level-scale. a). Descriptive System, 5-dimension-5-level-scale, scores are converted to a value where 1 equals 'perfect health' and 0 equals 'dead'. b). Visual Analogue Score, score 0 to 100 where 100 is the best health you can imagine and 0 = the worst health you can imagine.

    Time frame: From randomisation upto 6-8 weeks

  8. Quality of life, adverse events

    Adverse Event reporting, number of adverse events and their severity

    Time frame: From randomisation upto 6-8 weeks

  9. Quality of life, change

    Patient Clinical Global Impression of Change (PGIC) results, score 1-7 (1=very much improved, 7=very much worse).

    Time frame: From randomisation upto 6-8 weeks

07

Study locations

1 site
  • CPU Orion Pharma
    Espoo, Finland
08

References and documents

Publications

  • Eccleston C, Fisher E, Liikkanen S, Sarapohja T, Stenfors C, Jaaskelainen SK, Rice ASC, Mattila L, Blom T, Bratty JR. A prospective, double-blind, pilot, randomized, controlled trial of an "embodied" virtual reality intervention for adults with low back pain. Pain. 2022 Sep 1;163(9):1700-1715. doi: 10.1097/j.pain.0000000000002617. Epub 2022 Mar 25. PubMed 35324507 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2020 to primary completion in Oct 2023, 44 months.

Of 56 industry-sponsored interventional studies with no phase under Low Back Pain, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 44. This study's 44 months is above that.

Counting every sponsor, half of 1,290 studies reached it within 11 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2019
First posted
Jan 13, 2020
StartActual
Feb 4, 2020
Primary completionActual
Oct 31, 2023
CompletionActual
Oct 31, 2023
Last update
Nov 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04225884
Responsible party
Sponsor
First posted
Jan 13, 2020
Start date
Feb 4, 2020
Primary completion
Oct 31, 2023
Completion
Oct 31, 2023
Last update
Nov 8, 2023

Study contacts

Orion Pharma Clinical Study Director
study director · Orion Corporation, Orion Pharma

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion